Mytide Therapeutics is committed to providing peptides to serve a diverse array of applications.
Mytide Therapeutics has raised $7.0M in total funding. The most recent round was Series A. The last funding was announced in March 2022.
Mytide Therapeutics's investors include Alloy Therapeutics, National Science Foundation, Creative Destruction Lab, Massachusetts Life Sciences Center, Uncommon Denominator.
Mytide Therapeutics is headquartered in Boston, United States.
Mytide Therapeutics is committed to providing peptides to serve a diverse array of applications.
Mytide Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Mytide Therapeutics — Funding & Investors." VCBacked, March 8, 2022, https://www.vcbacked.co/company/mytide-therapeutics. Accessed August 14, 2026.
VCBacked. (2022). Mytide Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/mytide-therapeutics
{{cite web |title=Mytide Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/mytide-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated